RareResearch.AI
← Back to atlas

V779L

Category 4 — Stable Fold, Function DisruptedUncertain significanceLumenal · predictedσ-1 candidateSource card
ValineLeucine at position 779 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type V779 — hydrogen bond to I802
Fullscreen ↗
DynaMut2 mutant · V779L
Mutant L779 — hydrogen bond to R703 lost (3 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

3 lost4 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondR703Lost
Hydrogen bondD801D801Preserved
Hydrogen bondI802I802Preserved
Polar contactD801D801Preserved
Polar contactI802I802Preserved
CarbonylD801Gained
Van der WaalsG702Lost
Van der WaalsF704Gained
Van der WaalsD801Gained
HydrophobicF704Gained
HydrophobicI777I777Preserved
HydrophobicM781Lost
HydrophobicL804L804Preserved
HydrophobicI823I823Preserved
HydrophobicF825F825Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.60kcal/mol
Destabilising — mild
AlphaMissense
0.418
ambiguous
AlphaFold pLDDT
90
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Standard confidence · Lumenal

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsCataract 41; Wolfram-like syndrome; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram syndrome 1
Population frequency (gnomAD v4)Ultra-rare · AF 0.00050%
cDNA changec.2335G>T
ClinVar accessionVCV002189687
Last evaluated2024/03/25 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Uncertain significance for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.00050% · 8 / 1,612,842 alleles
Homozygotes
0
Highest-frequency population
African / African American · AF 0.0027%

Highest in African / African American: AF 0.0027% (2 of 74,938 alleles), 5.4x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
African / African American0.0027%2 / 74,9380~1 in 18730
Remaining individuals · under-sampled0.0016%1 / 62,4720
European (non-Finnish)0.00042%5 / 1,180,0300~1 in 118000

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — V779L Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Valine → Leucine at position 779. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.418, DynaMut2 ΔΔG -0.60 kcal/mol (destabilising).


Identity

FieldValue
VariantV779L (p.Valine779Leucine)
DNA changec.2335G>T
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV002189687
Amino acid changeValine (V) → Leucine (L)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 77990.12 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 779 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 779 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small hydrophobic (valine — branched); the mutant is medium hydrophobic (leucine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.4185
am_classambiguous
InterpretationLikely benign (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.6 (Destabilising)
Job ID178094699393
Result URLJob 178094699393 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300)

ClinVar classifies this variant as Uncertain significance for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2024/03/25 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeV779L is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Cataract 41
  • Wolfram-like syndrome
  • Autosomal dominant nonsyndromic hearing loss 6
  • Type 2 diabetes mellitus
  • Wolfram syndrome 1

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 4 — Stable Fold, Function Disrupted

<strong>Category 4 — Stable Fold, Function Disrupted</strong><br/><br/>|ΔΔG|=0.60 negligible. Likely site-specific functional disruption — docking strategy.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.60 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.418. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • V779L_molstar_viewer.html — interactive 3D viewer (auto-highlights position 779 with ball-and-stick + neighbors within 5Å)
  • V779L_variant_card.md — this card (source of truth)
  • V779L_variant_card.html — styled printable card
  • V779L_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • V779L_wildtype_interactions.pse / V779L_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the V779L PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download V779L PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.